Xu JM, Wang Y, Chen YL, Jia R, Li J, Gong JF, Li J, Qi C, Hua Y, Tan CR, Wang J, Li K, Sai Y, Zhou F, Ren YX, Qing WG, Jia H, Su WG, Shen L (2017) Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget 8:42076–42086. https://doi.org/10.18632/oncotarget.14942

Article  PubMed  PubMed Central  Google Scholar 

Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, Zhou Z, Li Z, Chi Y, Yu X, Li E, Xu N, Liu T, Lou W, Bai Y, Yuan X, Wang X, Yuan Y, Chen J et al (2022) Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. ESMO open 7:100453. https://doi.org/10.1016/j.esmoop.2022.100453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Syed YY (2021) Surufatinib: first approval. Drugs 81:727–732. https://doi.org/10.1007/s40265-021-01489-y

Article  CAS  PubMed  Google Scholar 

Chen J, Ji Q, Bai C, Zheng X, Zhang Y, Shi F, Li X, Tang P, Xu Z, Huang R, Huang T, Pan Y, Fan S, Zhou J, Su W (2020) Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter. Open-Label, Phase II Trial. Thyroid : official journal of the American Thyroid Association 30:1245–1253. https://doi.org/10.1089/thy.2019.0453

Article  CAS  PubMed  Google Scholar 

Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J et al (2020) Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study The Lancet. Oncology 21:1489–1499. https://doi.org/10.1016/s1470-2045(20)30493-9

Article  CAS  PubMed  Google Scholar 

Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X et al (2020) Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 21:1500–1512. https://doi.org/10.1016/s1470-2045(20)30496-4

Article  CAS  PubMed  Google Scholar 

Xu J, Li J, Bai C, Xu N, Zhou Z, Li Z, Zhou C, Jia R, Lu M, Cheng Y, Mao C, Wang W, Cheng K, Su C, Hua Y, Qi C, Li J, Wang W, Li K et al (2019) Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, Phase Ib/II Trial. Clinical cancer research 25:3486–3494. https://doi.org/10.1158/1078-0432.ccr-18-2994

Article  CAS  PubMed  Google Scholar 

Dasari A, Paulson S, Hamilton E, Wang J, Sung M, Falchook G, Tucci C, Li K, Chien C, Kauh J, Kania M, Li D (2020) Comparison of pharmacokinetic profiles and safety of surufatinib in patients from China and the United States [abstract no. CT115]. In: American Association for Cancer Research Annual Meeting

Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Current clinical pharmacology 3:132–143. https://doi.org/10.2174/157488408784293705

Article  CAS  PubMed  Google Scholar 

Qian H, Wu X, Chen Q, Li T, Wang W, Jia J, Yu C, Li K, Sai Y, Su W, Liu Y (2020) Effects of food on the pharmacokinetic properties of surufatinib: a phase I, single-dose, randomized, open-label crossover study in healthy subjects. Clinical therapeutics 42:1778–1786. https://doi.org/10.1016/j.clinthera.2020.07.010

Article  CAS  PubMed  Google Scholar 

Xu J, Bai Y, Sun H, Bai C, Jia R, Li Y, Zhang W, Liu L, Huang C, Guan M, Zhou J, Su W (2021) A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer 127:3975–3984. https://doi.org/10.1002/cncr.33803

Article  CAS  PubMed  Google Scholar 

Cao Y, Lu M, Sun Y, Gong J, Li J, Lu Z, Li J, Zhang X, Li Y, Peng Z, Zhou J, Wang X, Shen L (2023) Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. J Cancer Res Clin Oncol 149:779–789. https://doi.org/10.1007/s00432-021-03898-8

Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G (2016) Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 7:67661–67673. https://doi.org/10.18632/oncotarget.11813

Article  PubMed  PubMed Central  Google Scholar 

Zhang ZF, Wang T, Liu LH, Guo HQ (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PloS one 9:e90135. https://doi.org/10.1371/journal.pone.0090135

Article  PubMed  PubMed Central  Google Scholar 

Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, Yang CK, Peng MT, Huang CY, Chang WC, Hui RC, Yang CH, Yang SF, Chung WH, Su SC (2018) Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer management and research 10:1259–1273. https://doi.org/10.2147/cmar.s163391

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RC, Chang YC, Lu CW (2018) Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. Journal of immunology research 2018:5376476. https://doi.org/10.1155/2018/5376476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Wynsberghe M, Flejeo J, Sakhi H, Ollero M, Sahali D, Izzedine H, Henique C (2021) Nephrotoxicity of anti-angiogenic therapies. Diagnostics (Basel) 11:640. https://doi.org/10.3390/diagnostics11040640

Article  CAS  PubMed  Google Scholar 

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. The New England journal of medicine 358:1129–1136. https://doi.org/10.1056/NEJMoa0707330

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu X, Zhang S, Zhang T (2021) Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity. Cells 10:869. https://doi.org/10.3390/cells10040869

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Mantzourani M, Iliopoulos D, Perrea D, Barbetseas J, Papademetriou V (2018) The role of angiogenesis inhibitors in hypertension: following “Ariadne’s thread”. Am J Hypertens 31:961–969. https://doi.org/10.1093/ajh/hpy087

Article  CAS  PubMed  Google Scholar 

Font C, de Herreros MG, Tsoukalas N, Brito-Dellan N, Esposito F, Escalante C, Oo TH, Group MHS (2022) Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Support Care Cancer 30:8599–8609. https://doi.org/10.1007/s00520-022-06935-5

Article  PubMed  PubMed Central  Google Scholar 

Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, Capasso G (2021) Preventive strategies for acute kidney injury in cancer patients. Clin Kidney J 14:70–83. https://doi.org/10.1093/ckj/sfaa127

Article  CAS  PubMed  Google Scholar 

Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858–5866. https://doi.org/10.1158/1078-0432.ccr-11-0804

Cervantes CE, Kant S, Atta MG (2021) The link between conventional and novel anti-cancer therapeutics with thrombotic microangiopathy. Drug Metab Lett 14:97–105. https://doi.org/10.2174/1872312814666210716141633

Article  CAS  PubMed  Google Scholar 

Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M (2018) Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 73:990–1001. https://doi.org/10.1111/his.13716

Article  PubMed  Google Scholar 

Kaneko T, Shimizu A, Aoki M, Tsuruoka S (2015) A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 4:31–37. https://doi.org/10.1007/s13730-014-0135-0

Article  PubMed  Google Scholar 

Maruyama K, Chinda J, Kuroshima T, Kabara M, Nakagawa N, Fujino T, Yamamoto Y, Ohsaki Y, Ogawa Y, Hasebe N (2015) Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med 54:823–826. https://doi.org/10.2169/internalmedicine.54.3661

Article  CAS  PubMed  Google Scholar 

Awdishu L, Atilano-Roque A, Tuey S, Joy MS (2020) Identification of novel biomarkers for predicting kidney injury due to drugs using “omic” strategies. Pharmgenomics Pers Med 13:687–705. https://doi.org/10.2147/PGPM.S239471

Article  CAS  PubMed  Google Scholar